At −20 °C for 12 weeks, particle size, PDI, zeta potential, EE and protein expression were not significantly different from −80 °C storage; 4 °C and longer storage altered some parameters.
· PDF pp. 10 and 14, Fig. 4 and Discussion.sales@dcchemicals.com
ARV-T1
Formulation & Performance
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| ARV-T1 | 50 | Ionizable lipid |
| DSPC | 10 | Helper phospholipid |
| Cholesterol | 38.5 | Sterol |
| DMG-PEG2000 | 1.5 | PEG lipid |
| Reported total | Not reported | Source values retained |
Component molecular weights and calculated amounts
Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.
| Component | Molecular weight | Molar parts | Normalized mol% | Amount (µmol) | Weight (mg) |
|---|---|---|---|---|---|
| ARV-T1 | 50.000 | 69.3736 | 63.1654 | ||
| DSPC | 10.000 | 13.8747 | 10.9631 | ||
| Cholesterol | 38.500 | 53.4177 | 20.6539 | ||
| DMG-PEG2000 | 1.500 | 2.0812 | 5.2176 |
Calculated total: 100.0000 mg lipid.
Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.
Literature-reported performance for the cited formulation
Literature-reportedHigher than SM-102; catalog summary reports approximately 7-fold higher expressionHEK-293T cells, spike mRNA-LNP · SM-102PDF p. 9, Fig. 3D; article summary.
Literature-reportedStrong signal through 72 h, with approximately 50% of peak signal remaining at 72 hBALB/c mice, IM, 1 µg Luc mRNA, n=6 · SM-102 signal barely detectable at 72 hPDF p. 11, Fig. 5.
Literature-reported>10-fold higher at 0.01 and 0.1 µg than SM-102; 0.1 µg ARV-T1 similar to 1 µg SM-102BALB/c mice, prime day 1/boost day 21 · SM-102PDF p. 12, Fig. 6B–C.
Literature-reported>10-fold higher at 0.01 and 0.1 µg than SM-102; 0.1 µg ARV-T1 comparable to 1 µg SM-102Pseudotyped-virus neutralization, day 35 · SM-102PDF p. 12, Fig. 6D.
Literature-reportedNo abnormal blood biochemistry, histology or body-weight change reportedBALB/c mice, two injections 3 weeks apart · SM-102PDF p. 13, Fig. 7.
Additional reported findings
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetJeon JH, Zhu H, Qin J, et al. Lipid Nanoparticles Formulated with a Novel Cholesterol-Tailed Ionizable Lipid Markedly Increase mRNA Delivery Both in vitro and in vivo. International Journal of Nanomedicine. 2025;20:9389–9405. DOI: 10.2147/IJN.S527822
All formulation, performance and safety values are specific to the cited ARV-T1 LNP formulation, cargo, comparator, dose, route, species and time points.
All formulation, performance and safety values are specific to the cited ARV-T1 LNP formulation, cargo, comparator, dose, route, species and time points.